Methods for measuring, diagnosing, treating and managing metabolic syndrome

Abstract

The present invention relates to a method for measuring, diagnosing, treating and managing metabolic syndrome, including administering metabolic syndrome treatment drugs and pharmaceuticals to a patient in need of monitoring using an electronic device to prevent or reduce the risk of metabolic syndrome and related diseases, characterized in that it comprises the following steps: collecting and storing patient identification information and / or body measurement information in a database for incorporation into a medical record; referring the patient to a medical professional for medical record consultation; providing a pharmaceutical composition, supplying or supporting device comprising a pharmaceutical useful for preventing, reducing or controlling metabolic syndrome; connecting one or more measuring devices for measuring body metric information using an interactive user interface; measuring, recording and storing the collected body metric information in a database; the medical professional monitoring the patient's body metric information; and adjusting or maintaining a course of treatment.

Description

[Technical field]

[0001] The present invention relates to a useful method for the measurement, diagnosis, treatment and management of metabolic syndrome, including administration of formulations to prevent or reduce the risk of metabolic syndrome and related diseases, by remote medical care and distribution of formulations and supplies through the use of a user interface that allows for intercommunication between a physician and / or patient with a measurement device associated with a set of essential elements to meet treatment goals. [Background technology]

[0002] Metabolic syndrome is a constellation of risk factors that develop when at least three of the following are present: waist circumference 40 inches or more in men and 35 inches or more in women, triglycerides 150 milligrams per deciliter (mg / dL) or more of blood, high-density lipoprotein (HDL) cholesterol less than 40 mg / dL in men and less than 50 mg / dL in women, fasting blood glucose 100 mg / dL or more, systolic blood pressure 130 mmHg or more and / or diastolic blood pressure 85 mmHg or more, resulting in an increased risk of cardiovascular disease, diabetes, blood clots, fatty liver disease, and other health problems.

[0003] Metabolic syndrome can develop from lack of physical activity, overweight, obesity or genetic conditions and, if poorly treated or managed, can render an individual physically incapacitated and adversely affect their ability to carry out daily activities.

[0004] Specifically, overweight and obesity are defined as abnormal or excessive accumulation of fat that may be harmful to health. Currently, there are over 1.9 billion people aged 18 and over who are overweight, of which 650 million have some form of obesity, while over 380 million people under the age of 18 are overweight or obese, which the World Health Organization classifies as a global pandemic.

[0005] According to the US Centers for Disease Control and Prevention (CDC), body mass index (BMI) is weight (in kilograms) divided by height (in meters) squared, and a high BMI may be an indicator of excess body fat.

[0006] In this regard, the CDC suggests the following BMI ranges to identify the presence of overweight and obesity: -A BMI below 18.5 falls into the underweight range. - A BMI between 18.5 and 25 falls into the healthy weight range. - A BMI between 25.0 and 30 falls into the overweight range. - A BMI of 30.0 or higher falls into the obese range. Obesity is further subdivided into three classes according to BMI. - Class 1: BMI 30 or more and less than 35. - Class 2: BMI 35 or more and less than 40. - Class 3: BMI 40 or more, "severe" obesity.

[0007] Compared to people of a healthy weight, overweight people are at higher risk of many serious diseases and health conditions, including high blood pressure, high LDL cholesterol, low HDL cholesterol or high triglycerides (dyslipidemia), type 2 diabetes, coronary heart disease, stroke, gallbladder disease, osteoarthritis (destruction of cartilage and bone in the joints), sleep apnea and breathing disorders, some types of cancer, reduced quality of life, psychiatric disorders such as clinical depression, anxiety and other mental disorders, physical pain and impaired physical function.

[0008] As described above, obesity and overweight are major risk factors for the development of metabolic syndrome, but they are also easily detectable factors and can be prevented or managed at any stage.

[0009] Access to healthcare professionals who specialize in metabolic syndrome and related disorders is complicated by the fact that it is usually based on referral, or by choosing to self-treat without any contact with such professionals, or by using medications or exercise equipment to lose weight or improve one's health, and patients may discontinue or drop out of treatment due to lack of time / willingness to see a physician and physicians' time to adequately serve the patient, and lack of time / willingness to treat patients and a shortage of healthcare providers to provide it.

[0010] While there are many approaches to weight management or loss, patients commonly turn to dieting, exercise and therapy without a proper treatment plan or the assistance of a medical professional, which can result in patient distress, excessive weight gain after the diet ends, ill health and even death.

[0011] When treating overweight and obesity with dietary supplements or medicines, monitoring throughout treatment, and the participating health professionals, is essential to avoid compromising the patient's health. Summary of the Invention [Problem to be solved by the invention]

[0012] Since patients' health is compromised when it is difficult to continue preventive treatment or management of overweight, obesity and other factors of metabolic syndrome, a monitoring system is needed that is continuously accessible to healthcare professionals and has a drug or drug stocking system during the administration of medicines, with the aim of ensuring the supply of medicines, supplements, consumables, or support devices for quality and safe measurement, providing continuity and motivation to continue treatment, and, with the help of technology, monitoring in real time indicators that allow healthcare professionals to know the progress of treatment and evaluate whether the treatment plan needs to be changed or maintained.

[0013] It is an object of the present invention to provide a useful method for the measurement, diagnosis, treatment and management of metabolic syndrome, including administering medicines to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using or by means of an electronic device, thereby enabling the allocation of appropriate treatment, as well as the supply of medicines, consumables and supporting devices required for real-time monitoring by medical personnel.

[0014] As a specific objective, the present invention provides various tools that facilitate adherence to treatment and subsequently provide ongoing recommendations regarding routines, diet, frequency of medical appointments, exercise, etc., among other activities that allow for treatment reinforcement and monitoring by the medical practitioner.

[0015] Another specific object of the present invention is to maintain a constant relationship between the patient and the medical professional, ensuring uninterrupted communication of data on both sides; to maintain a constant connection between the patient and the drug provider, supplies or necessary support devices, avoiding discontinuation of treatment due to shortages thereof and to inform and remind the patient before any of them are terminated; and to maintain a connection between the patient and the measurement device, avoiding the need for data transfer or errors that may occur during the transfer.

[0016] The present invention relates to a method of management useful in the diagnosis, measurement and treatment of metabolic syndrome, which involves administering a pharmaceutical agent to prevent or reduce the risk of metabolic syndrome. [Means for solving the problem]

[0017] A method for treating metabolic syndrome and related diseases using an electronic device, comprising: (a) Collect and store in a database patient identifying and body metric information for incorporation into the medical record. (b) Refer the patient to a health care provider who has expertise in metabolic syndrome and related disorders to evaluate the patient's health status. (c) Informing patients of their health status and recording it in their medical records. (d) instructing patients on a course of treatment for metabolic syndrome and / or related disorders or prevention of metabolic syndrome and / or related disorders; (e) Providing to a patient in need thereof a pharmaceutical composition comprising a pharmaceutical agent useful for preventing, ameliorating, or managing metabolic syndrome and / or related disorders. (f) Providing consumables or supportive devices for the prevention, mitigation, or management of metabolic syndrome and / or related diseases to patients in need. (g) Using an interactive user interface, connecting one or more measurement devices for measuring body metric information. (h) Measure, record and store in a database any collected body metric information. (i) Medical professionals specializing in metabolic syndrome and related diseases will monitor patients' body metric information data and evaluate the patient's health status. (j) adjusting or maintaining a course of treatment for metabolic syndrome and / or related disorders from which a patient suffers, or preventing metabolic syndrome and / or related disorders; (k) Optionally, for a set period of time or at the request of the patient or healthcare professional, healthcare professionals may provide assistance to the patient. [Brief description of the drawings]

[0018] [Figure 1] FIG. 1 is a flow diagram illustrating an embodiment of the present invention. [Diagram 2] FIG. 4 is a flow diagram illustrating another embodiment of the present invention. [Diagram 3] FIG. 4 is a flow diagram illustrating alternative embodiments of the present invention. [Figure 4] FIG. 1 is a flow diagram illustrating an embodiment of a system for monitoring body metric information of the present invention. [Diagram 5] FIG. 4 is a flow diagram illustrating another embodiment of the present invention. [Figure 6] FIG. 2 is a flow diagram illustrating an embodiment of using a measuring device and associated electronic device for measuring body metric indicators of the present invention. [Figure 7] FIG. 2 is a flow diagram illustrating an embodiment of a medical worker's use of an electronic device according to the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] The following are descriptions of exemplary embodiments consistent with the description of the present invention, where the "exemplary embodiments" include certain aspects, structures, or features that may be combined with other exemplary embodiments, whether described or not, and thus the exemplary embodiments described below are not limiting and different software or hardware embodiments, interfaces, execution means, storage or reading, instructions, etc. may be implemented.

[0020] FIG. 1 is a diagram illustrating a useful method for the measurement, diagnosis, treatment and management of metabolic syndrome, including administering medications to a patient in need (100) to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, comprising the following features: Collecting (101) patient identification information (102a) and / or clinical parameters and / or body metric information (102c), which is information obtained when measuring body measurement indicators, etc., storing them in a database (103) and incorporating them into the medical record (102b), referring (111) the patient (100) to a medical professional (110) specializing in metabolic syndrome and related diseases for the evaluation of the patient's health status, presenting the patient's health status (111b) and recording it in the medical record (102b), and instructing the patient (111c) on a course of treatment for the metabolic syndrome and / or related diseases that the patient is suffering from, or a course of treatment for the prevention of metabolic syndrome and / or related diseases. and providing (121a) useful medicines (130) for the prevention, mitigation, or management of metabolic syndrome and / or related diseases to patients (100) in need thereof through a pharmacy (120). and providing (121b) to a patient (100) in need thereof a consumable (140a) or a support device (140b) for the prevention, mitigation, or management of metabolic syndrome and / or related diseases. Connecting (151) one or more measurement devices (140) for measuring body metric information using an interactive user interface (150). Measuring (141), recording (142) and storing (143) the collected body metric information (102c) in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the patient's (100) body metric information (102c) data and evaluates the patient's health condition. To adjust or maintain a course of treatment for the metabolic syndrome and / or related disorders from which the patient is suffering, or to prevent the metabolic syndrome and / or related disorders (113). Optionally, a medical professional (110) provides assistance (114) to the patient (100) at set time periods or upon request of the patient or medical professional.

[0021] FIG. 2 illustrates one embodiment of a useful method for the measurement, diagnosis, treatment and management of metabolic syndrome, including administering medications to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, comprising the following features: A pharmaceutical composition comprising a medicinal product (130) useful for preventing, reducing or managing metabolic syndrome and / or associated diseases is provided (121a) to a patient (100) from the patient's patient identification information (102a) and body metric information (102c) and / or medical records (102b) pre-stored in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) a patient's body metric information data via an interactive user interface (150) connected to one or more measurement devices for measuring the body metric information, and the interactive user interface (150) records (142) and stores (143) the body metric information.

[0022] FIG. 3 illustrates various embodiments of useful methods for measuring, diagnosing, treating, and managing metabolic syndrome, including administering medications to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device.

[0023] In one embodiment, a useful method for the measurement, diagnosis, treatment, and management of metabolic syndrome, comprising administering a pharmaceutical agent to a patient undergoing treatment prevention, mitigation, or management of metabolic syndrome and / or related diseases using an electronic device, the method comprising: Patient identification information (102a) and / or body metric information (102c) are collected (101) and stored in a database (103) to incorporate a medical record (102b). Through the pharmacy (120), a pharmaceutical composition containing a useful drug (130) for preventing, alleviating or managing metabolic syndrome and / or related diseases is provided (121a) to a patient (100) in need thereof based on patient identification information (102a) and the patient's body metric information (102c) and / or information in the patient's medical record (102b) previously stored in a database. Body metric information (102c) collected from the patient during treatment is measured (141), recorded (142) and stored (143) in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the patient's (100) body metric information (102c) data to assess the patient's health status, adjust or maintain a treatment plan (113) for treating the metabolic syndrome and / or related diseases suffered by the patient, or prevent the metabolic syndrome and / or related diseases.

[0024] In one embodiment, a method useful for measuring, diagnosing, treating, and managing metabolic syndrome comprises administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, characterized in that the method comprises the steps of: The patient (100) is referred (111) to a medical professional (110) who specializes in metabolic syndrome and related disorders for an evaluation of the patient's health status, the patient's health status (111b) is presented, and recorded in the medical record (102b), and the patient is instructed (111c) on a course of treatment for the metabolic syndrome and / or related disorders from which the patient suffers, or a course of treatment for the prevention of metabolic syndrome and / or related disorders. A pharmaceutical composition containing a pharmaceutical agent (130) useful for preventing, reducing, or managing metabolic syndrome and / or related diseases is provided (121a) to a patient (100) in need thereof through a pharmacy (120). Body metric information (102c) collected from the patient during treatment is recorded (142) and stored (143) in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the patient's (100) body metric information (102c) data and evaluates the patient's health condition. Adjust or maintain a course of treatment for the metabolic syndrome and / or related disorders from which the patient is suffering, or for the prevention of the metabolic syndrome and / or related disorders (113).

[0025] In another embodiment, a useful method for the measurement, diagnosis, treatment, and management of metabolic syndrome, comprising administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, characterized in that the method comprises: A pharmaceutical composition containing a pharmaceutical agent (130) useful for preventing, reducing, or managing metabolic syndrome and / or related diseases is provided (121a) to a patient (100) in need thereof through a pharmacy (120). Through a pharmacy (120), consumables (140a) or support devices (140b) are provided (121b) to a patient (100) in need thereof for the prevention, mitigation, or management of metabolic syndrome and / or related diseases. One or more measuring devices (140) for measuring body metric information are connected (151) with an interactive user interface (150). The collected body metric information (102c) is measured (141), recorded (142), and stored (143) in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the patient's (100) body metric information (102c) data and evaluates the patient's health condition. Adjust or maintain a course of treatment for the metabolic syndrome and / or related disorders from which the patient is suffering, or for the prevention of the metabolic syndrome and / or related disorders (113).

[0026] In another embodiment, a useful method for the measurement, diagnosis, treatment, and management of metabolic syndrome, comprising administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases by using an electronic device, characterized in that the method comprises: A pharmaceutical composition including a pharmaceutical agent (130) useful for preventing, mitigating, or managing metabolic syndrome and / or related disorders is provided (121a) to a patient (100) in need thereof through a pharmacy (120). An interactive user interface (150) is used to connect (151) one or more measurement devices (140) for measuring body metric information. The collected body metric information (102c) is measured (141), recorded (142), and stored (143) in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the patient's (100) body metric information (102c) data and evaluates the patient's health condition. Adjust or maintain a course of treatment for the metabolic syndrome and / or related disorders from which the patient is suffering, or for the prevention of the metabolic syndrome and / or related disorders (113).

[0027] 4 illustrates an embodiment of a system for monitoring at least one body metric information for a patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases. The system includes an electronic device and interface (160a) for entering patient identification information and / or body measurement information into a database. The device and interface (160b) for collecting and storing patient identification and / or anthropometric information in a database for incorporation into a medical record; means for accessing (170) between the patient and a medical professional specializing in metabolic syndrome and related diseases for evaluating the patient's health status; means for displaying the health status to the patient and recording it in the medical record (170a); means for instructing the patient on a course of treatment for the treatment or prevention of metabolic syndrome and / or metabolic syndrome related diseases from which the patient is suffering (170b); means for providing (121a) to a patient in need (100) a pharmaceutical composition comprising a medicament useful for the prevention, mitigation or management of metabolic syndrome and / or related diseases; means for providing consumables or support devices for the prevention, mitigation or management of metabolic syndrome and / or related diseases to a patient in need (100). means for providing (121b) to the patient; means for connecting (152) with an interactive user interface to one or more measuring devices for measuring body metric information; a database (103) for recording and storing the collected body metric information; a means for a medical professional specializing in metabolic syndrome and related diseases to monitor (112) the patient's body metric information data in order to assess the patient's health status; access means for the medical professional to adjust or maintain a treatment plan (113) for the treatment of metabolic syndrome and / or related diseases or for the prevention of metabolic syndrome and / or related diseases from which the patient suffers; and access means for establishing (114) communication between the patient and the medical professional, optionally at set time periods or upon request of the patient or the medical professional.

[0028] FIG. 5 is a diagram illustrating an embodiment of a useful method for measuring, diagnosing, treating, and managing metabolic syndrome, comprising administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, characterized in that the method comprises the steps of: The present invention provides a patient and a medical professional with a therapeutic or preventive monitoring system (200), the monitoring system including at least an electronic device and interface (160a) for inputting patient identification information and / or body metric information into a database, a device and interface (160b) for collecting and storing patient identification information and / or body metric information in a database for incorporation into a medical record, a means for communication between the patient and a medical professional specializing in metabolic syndrome and related diseases, and an access (170) for evaluating the health status of the patient, a means for indicating and recording the health status of the patient in the medical record (170a), and a means for instructing the patient on a course of treatment for the metabolic syndrome and / or related diseases from which the patient is suffering, or a course of treatment for the prevention of metabolic syndrome and / or related diseases (170b), and a pharmaceutical composition comprising a pharmaceutical agent useful for the prevention, mitigation, or management of metabolic syndrome and / or related diseases, for a patient in need thereof. means for providing (121a) to a patient in need thereof; means for providing (121b) to a patient in need thereof supplies or support devices for the prevention, mitigation or management of metabolic syndrome and / or related diseases; means for connecting (152) by using an interactive user interface for one or more measuring devices for measuring body metric information; a database (103) for recording and storing the collected body metric information; means for a medical professional specializing in metabolic syndrome and related diseases to monitor (112) the data of the patient's body metric information to evaluate the patient's health status; means for the medical professional to access in order to adjust or maintain a course of treatment (113) for the treatment of the patient's metabolic syndrome and / or related diseases or for the prevention of metabolic syndrome and / or related diseases; optionally, means for establishing (114) communication between the patient and the medical professional for a set period of time or at the request of the patient or the medical professional;providing the patient (100) with a pharmaceutical composition comprising a pharmaceutical agent (130) useful for preventing, reducing or managing metabolic syndrome and / or related diseases from the patient's patient identification information and body metric information or medical records previously stored in a database;

[0029] A medical professional (110) specializing in metabolic syndrome and related diseases uses an interactive user interface connected to one or more measurement devices for measuring body metric information to monitor data of the patient's body metric information and evaluate the patient's health condition.

[0030] FIG. 6 shows a system for monitoring at least one body metric information of a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using a measuring device and associated electronic device for measuring body metric information, characterized in that it includes: a patient monitoring module mounted in a patient electronic device and interface (160a), at least one measuring device (140) for measuring body metric information connectable to the patient electronic device and interface (160a), and a means of communication (180) between the patient electronic device and interface (160a) and the measuring device for measuring body metric information, the patient monitoring module (i) collecting (101) patient identification information (102a) and / or body metric information (102c), (ii) recording (142) and storing (143) the measured (141) body metric information (102c) of the patient in a database (103), and (iii) storing said information in the database (103) for incorporation into a medical record (102b). (iv) referring (111) the patient (100) to a medical professional (110) who specializes in metabolic syndrome and / or related disorders, evaluating the patient's health status, providing the patient with a health status (111b), recording the status in the medical record (102b), and instructing the patient on a course of treatment (111c) for the treatment of metabolic syndrome and / or related disorders or for the prevention of metabolic syndrome and / or related disorders. (v) providing (121a) through the pharmacy (120) to the patient (100) in need thereof pharmaceutical compositions including drugs (130) useful for the prevention, reduction or management of metabolic syndrome and / or related disorders, as well as consumables (140a) or support devices (140b). (vi) establishing a connection (151) with at least one measuring device (140) for measuring body metric information. (vii) Measuring (141), recording (142), and storing (143) body metric information (102c) in a database (103).(viii) measuring (141), recording (142) and storing (143) in a database (103) body metric information (102c) obtained from at least one measuring device (140) for measuring body metric information, (vii) allowing a medical professional (110) specializing in metabolic syndrome and related diseases to access (170) the patient's medical records in order to evaluate the patient's health status and adjust or maintain the course of treatment (113), and optionally (ix) establishing (114) communication between the patient (100) and the medical professional (110) at set time periods or upon request of the patient or the medical professional.

[0031] FIG. 7 shows a connectivity model of a monitoring system linking at least one body metric information to a patient (100) in need of a pharmaceutical composition comprising a pharmaceutical product (130) useful for preventing, reducing, or managing metabolic syndrome and / or related diseases, using an electronic device associated with a measuring device (140) for measuring the body metric information, the system including a user interface, communication means, and a database.

[0032] The patient, healthcare professional or third party authorized to access the information stored in the interface or database can visualize the body metric information through the interface, as well as patient information and records. This information is provided to the patient or authorized third party to indicate the normal range of measurements, to indicate if there are risk factors that should be addressed, and to indicate the achieved progress of the treatment, allowing both the patient and the healthcare professional or third party authorized to monitor to take prompt action to achieve the goals of the treatment.

[0033] The electronic device and interface (160a) for entering patient identification information and / or body metric information into the database, and the device and interface (160b) for collecting patient identification information and / or body metric information and storing it in the database and incorporating it into the medical record, may be a laptop or desktop computer, an electronic tablet, a smart display, a smart screen, a smart mobile phone, a video game console, a media player device, a smart watch, a smart bracelet, or any device that allows data to be entered by text, voice, or some other encoding and that can be connected by wire or wirelessly.

[0034] In a non-limiting embodiment, the referral (111) of the patient (100) to a medical professional (110) specializing in metabolic syndrome and related disorders is performed by video call using an electronic device with pre-identification of the patient and medical professional to assess the patient's health status. Once the link is established, medical paperwork is performed and all information from the patient's file or in situ measurements using a measuring device that measures body metric information is integrated to obtain a doctor's treatment course of treatment and a dispensing order to provide a pharmaceutical composition including a drug useful for preventing, reducing, or managing metabolic syndrome and / or related disorders.

[0035] Patient and medical personnel identification may be accomplished through a number of embodiments, such as a password, identification number, username, or biometric authentication (fingerprint, retina, or facial identification), identification card, or other means of identification.

[0036] A user interface for both the patient and the medical personnel can be connected to one or more screens, printers, speakers, and / or other devices for operation. The interface can include notifications, links, buttons, tabs, checkboxes, bullets, text fields, drop boxes, etc., and can provide a variety of outputs in response to user input, such as text, still images, video, audio, and animation.

[0037] The connection may be selected from a local area network, a wireless local area network, a tree or ring topography network, a wireless Internet point of presence system, Ethernet, Internet, wireless communication, infrared, fiber optics, 2G, 3G, 4G, or 5G data telephony.

[0038] Pharmaceutical compositions containing useful pharmaceutical agents (130) for preventing, reducing, or managing metabolic syndrome and / or related disorders include pharmaceutical agents for preventing, reducing, or managing overweight, obesity, hyperglycemia (type I or type II diabetes), hypertension, heart disease, dyslipidemia, and other related disorders.

[0039] In a preferred embodiment, the pharmaceutical composition comprising a useful medicament (130) for the prevention, reduction, or management of metabolic syndrome and / or related diseases is a formulation for the prevention, reduction, or management of overweight and obesity, comprising a chemical uncoupler of oxidative phosphorylation, tyrphostin AG17, orlistat, L-carnitine, benzphetamine, phendimetrazine, diethylpropion, liraglutide, naltrexone, phentermine, topiramer. , glibenclamide, metformin, acarbose, canagliflozin, dapagliflozin, saxagliptin, dulaglutide, empagliflozin, exenatide, lixisenatide, semaglutide, CBD, sibutramine, hydroxycitric acid, coenzyme q10, chromium picolinate, gamma-linolenic acid, resveratrol, omega-3 fatty acids, antioxidants, vitamins, vitamin B, vitamin C, adrenal extract, pantothenic acid, turmeric longa, Bayberry bark, Myrica cerifera, Oryza sativa L. indica, Camellia sinensis, Theobroma cacao, Emblica officinalis, Ilex paraguariensis, Cascara sagrada bark, Rhamnus purshiana, Acacia nilotica, Persimmon, Blueberry leaf, Grape seed, Cordia salicifolia, Hypericum perforatum, Pueruria thomsonn, Capers spinosa), Gymnema sylvestre, Elderberry, Sambicus, Citrus aurantium, Coffea canefora, Sygium cumini,Rosemary (Rosmarinus officinalis), Ginger (Zingiber officinalis), Cassia nomame, Cissus quadrangularis, Phaseolus vulgaris, Licorice Root, Fenugreek, Yohimbe, White willow, Cordyceps sinensis, Ashwaganda, Astragalus, Gingseng, Schisandra, Siberian gingseng, Asian gingseng, Guggul, Gagal, Mukul, Momordica charantia, Garcinia cambogia, Marshmallow (Althaea officinalis), Bougainvillea spectabilis, Medicago sativa, Valeriana officinalis, Damiana, Sambucus nigra), Capsicum spp., Allium spp., calcium myristate, magnesium myristate, tetradecylthioacetic acid (TTA), thyroid hormones or precursors thereof, thyrotropic agents, Kreb cycle metabolites, UCP-1, UCP-2, UCP-3, endogenous uncoupling protein or precursors of PUMP (plant uncoupling mitochondrial protein), agonists or enhancers, leucine, valine, isoleucine, glutamine, proline, tyrosine, conjugated linoleic acid, adrenergic secretagogues, fatty acids or esters, beta agonists, glucagon, arbutamine, vasopressin, ubiquinone, coenzyme Q1, coenzyme Q2, melatonin, fatty acid esters of estrogens such as oleylestrone, glucomannan, menthol, peppermint essential oil, thyme essential oil, elemental sulfur and policosanol, insulin or insulin analogues,and oral hypoglycemic agents; acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, tolazamide, tolbutamide, (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3, 4, 5-triol or Glyset)(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)-cyclohexane-1,2,3,4-tetraol), (RS)-5-[4-(2-[methyl (pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, (RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione, 5-[(4-[2-([6-(4-methoxyphenoxyl)pyrimidin-4-yl]-methylamino)ethoxy]phenyl-methyl]-1,3-thiazolidine-2,4-dione, (RS)-5-(4-[( 6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)thiazolidine-2,4-dione, (S)-(+)-2-ethoxy-4-[2-(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino)-2-oxoethyl]benzoic acid, 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid, (2S)-2-benzyl-4- [(3aR,7aS)-Octahydro-2H-isoindol-2-yl]-4-oxobutanoic acid, L-ornithine, L-tyrosine, L-tryptophan, L-phenylalanine, conjugated linoleic acid, gamma-linolenic acid, chromium picolinate, glucose tolerance factor, vanadyl sulfate, Gymnema sylvestre, bromelain, pancreatin, Pagymnema sylvestre 10, curcumin, barberry, bearberry, silymarin, Drosophila melanogaster D, choline, inositol, human growth hormone, DHEA (e.g., fucoxanthin), caffeine, xanthenes, cola nut, psyllium, yerba mate, guarana, ginseng, medium-chain triglycerides, hydroxycitric acid (HCA), kelp, lecithin, dihydroxyacetone, pyruvic acid, creatine, iodine, niacin, bladderwrack, white kidney bean extract, glucomannan, chitosan, resveratrol,Resveratrol derivative, Vitamin D, hCG, Capsaicin, Chia, Hoodia, Apple Cider Vinegar, Coconut Oil, Bitter Orange, B Vitamins, Fluoxetine, Chitosan, Chromium Picolinate, Conjugated Linoleic Acid (CLA), Glucomannan, Green Tea Extract, Green Tea Extract, Guar Gum, Hoodia, 7-Keto-DHEA, DHEA, Ephedra, Bitter Orange, Turmetic, Ginger, Root Powder, Apple Cider Vinegar, Calcium, Hesperidin, Apanthenol Gynostemma, Flaxseed Oil, Orange Peel Powder, Thiamine, Ashwagandha Extract, Coffee Extract, L-Theanine, Heavy Alcohol Choline nitrate, red mango extract, white kidney bean extract, C. cinephora robusta extract, acetyl-L carnitine, Garcinia cambogia, cumbusia extract, coconut oil, forskolin extract, black pepper extract, seroxat, citalopram, bupropion, topiramate, ecopipam, naltrexone, peptide YY3-36, leptin, exemphetamine, amphetamine, phentermine, mazindol phendimetrazine, diethylpropion, fenfluramine, dexfenfluramine, pharmaceutically acceptable salts and derivatives thereof and mixtures thereof.

[0040] In another embodiment, the pharmaceutical composition containing the pharmaceutical agent (130) useful for the prevention, alleviation, or management of metabolic syndrome and / or related diseases is selected from the group consisting of chemical uncouplers of oxidative phosphorylation, biguanides, imidazolines, α-glucosidase inhibitors, meglitinidas, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, sulfonylureas, potassium channel blockers such as nateglinide or BTS-67582, glucagon antagonists, inhibitors of DPP-IV (dipeptidyl peptidase-IV), inhibitors of PTPasa (protein tyrosine phosphatase), glucokinase activators, enzymes and metabolites involved in the regulation of gluconeogenesis or glycogenolysis, glucose uptake modulators, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds that modify lipid metabolism such as hyperlipidemic therapeutics, antilipidemic therapeutics, compounds that reduce food intake, PPAR agonists; e.g., tyrphostin AG, Tyrphostin A9, insulin and insulin analogues, tolbutamide, chlorpropamide, tolazamide, glibenclamide, glipizide, glimepiride, glicazide / glyburide, metformin, repaglinide or senaglinide / nateglinide, troglitazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, GI262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP- 297, GW-409544, CRE-16336, AR-H, voglibose, emiglitate, miglitol / acarbose, tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582o repaglinide, nateglinide, cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, pharma- ceutically acceptable salts and derivatives thereof, and mixtures thereof.

[0041] In another embodiment, the pharmaceutical composition containing a useful pharmaceutical agent (130) for the prevention, reduction, or management of metabolic syndrome and / or related diseases comprises a pharmaceutical agent for the prevention, reduction, or management of hypertension selected from the following: alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and [alpha]-blockers such as doxazosin, urapidil, prazosin and terazosin, pharmaceutically acceptable salts and derivatives thereof, and mixtures thereof.

[0042] Chemical uncouplers for oxidative phosphorylation include, but are not limited to, the following compounds: 4,4-bis-(4-hydroxy-3-nitrophenyl)valeric acid, 4-methoxy-2-nitrophenol, 4-hydroxy-3-nitroacetophenone, 7-hydroxy-4-methyl-8-nitrochromen-2-one, 3-tert-butyl-5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-methylbenzamide, N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3-methyl-2-propanediol, and N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3-methyl-2-propanediol. ,5-Di-(trifluoromethyl)benzamide, N-(4-cyanophenyl)benzamide, 2'-chloro-1-hydroxy-4'-nitro-2-naphthanilide, N-(2-chloro-4-bromophenyl)-5-bromosalicylanilide, N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylanilide, (3,5-di-tert-butyl-4-hydroxybenzyl)triphenylphosphonium bromide, 3,5-di-tert-butyl-4-hydroxybenzyl)tricyclohexylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tributylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)trioctylphosphonium bromide, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)malonic acid diethyl ester, 2-amino-S-[(3,5-di-tert-butyl-4-hydroxybenzylidene)-amino]but-2-ene 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)-indan-1,3-dione, 2-malononitrile, 2-(4-chlorophenyl)-indole, N-(2,4,5-trichlorophenyl)salicylanilide, 2,3-dimethyl-5-cyano-7-ethylindole, 4-bromo-2-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrrole-3-carbonitrile, N-(5,7-dimethyl-1H-indol-3-ylmethylene)-3-trifluoromethyl-benzamide, 2,4-Dinitrophenol, carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone, 2-(5-bromo-1H-indol-3-ylmethylene)-malononitrile, 2-((5-chloro-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-(2-phenyl-3-indolylmethylene)malononitrile 2-(2-chloro-1H-indol-3-ylmethylene)malononitrile, 2-(5-nitro-1H-indol-3-ylmethylene)malononitrile, 2-(2-methyl-5-nitro-1H-indol-3-ylmethylene)malononitrile, 3-bromo-5-tert-butyl-N-(2-chloro-4-nitrophenyl)-6-hydroxy-2-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropylbenzamide amide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-6-methylbenzamide, 3,5-di-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide, 3-bromo-N-(2-chloro-4-nitrophenyl)-6-hydroxy-5-isopropyl-2-methylbenzamide, 3-tert-butyl-5-chloro-N-(4-chloro-3-trifluoromethylphenyl)-2-hydroxy-6-methyl-benzamide amide, 3-tert-butyl-5-chloro-N-(4-cyano-3-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 2-hydroxybiphenyl-3-carboxylic acid (2-chloro-4-nitrophenyl)-amide, 3-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxy-5-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-isopropyl-3-methylbenzamide, N-(3,5-bistrifluoromethylphenyl)-3-tert-butyl-5-chloro-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-N-(2-fluoro-5-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-3-trifluoromethylphenyl)benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3 -Bromo-5-tert-butyl-N-(2-chloro-4-cyanophenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(2-chloro-5-trifluoromethylphenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methyl Benzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-{5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl}-6-hydroxy-2-methylbenzamide, 3-bromo-6-hydroxy-5-isopropyl-2-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N- (4-nitro-2-trifluoromethylphenyl)benzamide, 3-tert-butyl-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-N-(3,5-di-tert-butyl-4-hydroxyphenyl)-5-tert-butyl-6-hydroxy-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-bromo-5-tert-butyl-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-[(3,5-di-tert-butyl-4-hydroxybenzylidene)amino]-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-6-hydroxy-N-(4-isopropyl-2-trifluoromethylphenyl)-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-fluoro-5-trifluoromethylbenzamide, 3-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-5-trifluoromethylbenzamide, N-(2,4,5 -trichlorophenyl)-3-fluoro-4-trifluoromethylbenzamide, 4-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-3-trifluoromethylbenzamide, 3-(3,5-di-tert-butyl-4-hydroxyphenyl-2-(5,7-dimethyl-1H-indol-3-ylmethylene)acrylonitrile, 2-acetyl-3-(3,5-bis-trifluoromethylphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononyl tolyl, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononitrile, 2,6-di-tert-butyl-4-nitrophenol, 2-tert-butyl-4,6-dinitrophenol, 3-(3,5-di-tert-butyl-4-hydroxybenzyl)-2-pyridin-2-yl-acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)malononitrile, 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-(diethylphosphonate)propenenitrile , 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-nitrophenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-pyridin-4-yl-acrylonitrile, 2-(3,5-bis-trifluoromethylphenyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethoxyphenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethyl-phenyl)acrylonitrile, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)but-2-enoic acid ethyl ester, N-(4-chlorophenyl)-2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylamide, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methanesulfonylacrylonitrile, (E)-2-(4-chlorobenzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-fluorobenzenesulfonyl)acrylonitrile, (E)-2-benzenesulfonyl-3- (3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-bis-trifluoromethylphenyl)-2-(propane-2-sulfonyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(hexane-1-sulfonyl)acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 2-(4-bromo-benzenesulfonyl)-3-acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)acrylonitrile, 5-bromo-3-tert-butyl-N-(2-chloro-4-cyanophenyl)-2-hydroxybenzamide, 5-bromo-3-tert-butyl-N-(4-cyanophenyl)-2-hydroxybenzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(2-trifluoromethylphenyl)benzamide, 2-(2-bromo-1H-indol-3-ylmethylene)malononitrile, 2-(7-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, 2-(5-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, pharma- ceutically acceptable salts thereof, derivatives thereof and mixtures thereof.

[0043] The body metric information is selected from the following: weight, BMI, body fat percentage, height, muscle, water, visceral fat, bone, metabolism, protein, obesity level, body age, lean body mass, oxygenation, body oxygenation quantified in urine, vitamins and minerals, blood glucose, blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, urine glucose, pedometer, heart rate, fasting blood glucose, post-load blood glucose, total cholesterol, total bilirubin, alanine transaminase, aspartate aminotransferase and / or body temperature.

[0044] Measurement devices (140) for measuring body metric information, which is information obtained when measuring clinical parameters and / or body measurement indicators, etc., may be selected from, but are not limited to, weight scales, ORP, vitamin sticks, blood glucose meters, oximeters, smart watches, smart bracelets, smart clothing, patches, tattoos, implants, hearing aids, helmets, electrodes, chest bands, pedometers, and / or medical instruments and devices for quantifying biochemical parameters. [Explanation of symbols]

[0045] 100...patient, 101...collection, 102a...patient identification information, 102b...medical record, 102c...body metric information, 103...database, 110...healthcare professional, 112...monitoring, 113...treatment policy, 120...pharmacy, 130...medicine, 140...measuring device, 150...interactive user interface.

Claims

1. A method for measuring, diagnosing, treating and managing metabolic syndrome comprising administering a pharmaceutical agent to a patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, the method comprising the following features: (a) Patient identification information (102a) and / or body metric information (102c) are collected (101) and stored in a database (103) for incorporation into the medical record (102b). (b) referring (111) the patient (100) to a medical professional (110) who specializes in metabolic syndrome and related disorders to evaluate the patient's health status; (c) presenting said medical condition (111b) to said patient and recording it in their medical record (102b); (d) instructing the patient (111c) on a course of treatment for the metabolic syndrome and / or related disorders or prevention of the metabolic syndrome and / or related disorders. (e) providing (121a) through a pharmacy (120) a pharmaceutical composition comprising a pharmaceutical agent (130) useful for preventing, mitigating, or managing metabolic syndrome and / or related disorders to said patient (100) in need thereof. (f) providing (121b) through said pharmacy (120) consumables (140a) or support devices (140b) for the prevention, mitigation, or management of metabolic syndrome and / or related diseases to said patient (100) in need thereof. (g) connecting (151) one or more measuring devices (140) for measuring said body metric information using an interactive user interface (150). (h) measuring (141), recording (142) and storing (143) the collected body metric information (102c) in a database (103); (i) A medical professional (110) specializing in the metabolic syndrome and related diseases monitors (112) the body metric information (102c) of the patient (100) and evaluates the health condition of the patient. (j) adjusting or maintaining a treatment regimen (113) for treating metabolic syndrome and / or related disorders from which said patient suffers, or for preventing metabolic syndrome and / or related disorders from which said patient suffers. (k) Optionally, said medical personnel (110) provides assistance (114) to said patient (100) at defined time periods or upon request of the patient or medical personnel.

2. 1. A method for measuring, diagnosing, treating and managing metabolic syndrome, comprising administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, the method comprising the following features: (a) providing (121a) to the patient (100) a pharmaceutical composition comprising a pharmaceutical agent (130) useful for preventing, alleviating or managing metabolic syndrome and / or related disorders, from patient identification information (102a) and body metric information (102c) previously stored in a database (103) and / or from the patient's medical record (102b); (b) a medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) data of the patient's body metric information using an interactive user interface (150) connected to one or more measuring devices for measuring the body metric information, and the interactive user interface (150) records (142) and stores (143) the body metric information.

3. A method for measuring, diagnosing, treating, and managing metabolic syndrome, comprising administering a pharmaceutical agent to a patient undergoing treatment for the prevention, mitigation, or management of metabolic syndrome and / or related diseases using an electronic device, the method comprising the following features: (a) Patient identification information (102a) and / or body metric information (102c) are collected (101) and stored in a database (103) for incorporation into the medical record (102b). (b) providing (121a) through a pharmacy (120) to the patient (100) in need thereof a pharmaceutical composition comprising a pharmaceutical product (130) useful for the prevention, alleviation or management of metabolic syndrome and / or associated diseases from the patient identification information (102a) and the patient's body metric information (102c) and / or medical records (102b) previously stored in the database. (c) measuring (141), recording (142) and storing (143) the patient's body metric information (102c) collected during treatment in the database (103); (d) requesting a medical professional (110) who specializes in metabolic syndrome and related diseases to evaluate the health condition of the patient (100) and monitor (112) the body metric information (102c) data of the patient (100); (e) adjusting or maintaining a treatment regimen (113) for treating the metabolic syndrome and / or related disorders from which said patient suffers, or for preventing the metabolic syndrome and / or related disorders.

4. A method for measuring, diagnosing, treating, and managing metabolic syndrome, comprising administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, the method comprising the following features: (a) referring (111) the patient (100) to a medical professional (110) who specializes in metabolic syndrome and related disorders, who evaluates the patient's health status; (b) presenting said medical condition (111b) to said patient and recording it in their medical record (102b); (c) instructing the patient (111c) on a course of treatment for metabolic syndrome and / or related disorders or prevention of metabolic syndrome and / or related disorders. (d) providing (121a) through a pharmacy (120) a pharmaceutical composition comprising a pharmaceutical agent (130) useful for preventing, mitigating, or managing metabolic syndrome and / or related disorders to said patient (100) in need thereof. (e) Recording (142) and storing (143) in a database (103) body metric information (102c) collected from the patient during treatment. (f) A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the body metric information (102c) data of the patient (100) and evaluates the health condition of the patient. (g) adjusting or maintaining a treatment regimen (113) for treating the metabolic syndrome and / or related disorders from which said patient suffers, or for preventing the metabolic syndrome and / or related disorders from which said patient suffers.

5. A method for measuring, diagnosing, treating and managing metabolic syndrome, comprising administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, the method comprising the following features: (a) providing (121a) through a pharmacy (120) to said patient (100) in need thereof a pharmaceutical composition comprising a pharmaceutical agent (130) useful for preventing, mitigating, or managing metabolic syndrome and / or related disorders; (b) providing (121b) through said pharmacy (120) consumables (140a) or support devices (140b) for the prevention, mitigation, or management of metabolic syndrome and / or related diseases to a patient (100) in need thereof. (c) connecting (151) one or more measurement devices (140) for measuring body metric information using an interactive user interface (150); (d) measuring (141), recording (142) and storing (143) the collected body metric information (102c) in a database (103); (e) A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the body metric information (102c) of the patient (100) and evaluates the health condition of the patient. (f) adjusting or maintaining a treatment regimen (113) for treating the metabolic syndrome and / or related disorders from which said patient suffers, or for preventing the metabolic syndrome and / or related disorders.

6. A method for measuring, diagnosing, treating and managing metabolic syndrome, comprising administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, the method comprising the following features: (a) providing (121a) through a pharmacy (120) to said patient (100) in need thereof a pharmaceutical composition comprising a pharmaceutical agent (130) useful for preventing, mitigating, or managing metabolic syndrome and / or related disorders; (b) using an interactive user interface (150) to connect (151) one or more measurement devices (140) for measuring body metric information; (c) The collected body metric information (102c) is measured (141), recorded (142), and stored (143) in a database (103). (d) A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the body metric information (102c) data of the patient (100) and evaluates the health condition of the patient. (e) adjusting or maintaining a treatment regimen (113) for treating the metabolic syndrome and / or related disorders from which said patient suffers, or for preventing the metabolic syndrome and / or related disorders.

7. A system for monitoring at least one body metric information of a patient (100) in need thereof, using a measuring device and an associated electronic device for measuring said body metric information in order to prevent or reduce the risk of metabolic syndrome and related diseases, characterized in that the system comprises: (a) a patient monitoring module installed in said patient electronic device and interface (160a); (b) at least one measuring device (140) for measuring said body metric information connectable to said electronic device and interface (160a) of said patient; (c) communication means (180) between said electronic device and interface (160a) of said patient and said measuring device (140) for measuring said body metric information; The patient monitoring module is configured to (i) collect (101) patient identification information (102a) and / or the body metric information (102c), (ii) record (142) and store (143) the measured (141) body metric information (102c) of the patient in a database (103), and (iii) store the information in the database (103) for incorporation into a medical record (102b). (iv) referring (111) the patient (100) to a medical professional (110) who specializes in metabolic syndrome and / or related disorders, evaluating the patient's health status, informing the patient of the health status (111b), recording the same in the medical record (102b), and instructing the patient on a course of treatment (111c) for the treatment of metabolic syndrome and / or related disorders or the prevention of metabolic syndrome and / or related disorders; (v) providing (121a) through a pharmacy (120) to the patient (100) in need thereof pharmaceutical compositions including medicinal products (130) useful for the prevention, mitigation or management of metabolic syndrome and / or related disorders, as well as consumables (140a) or support devices (140b). (vi) establishing a connection (151) with at least one measuring device (140) for measuring the body metric information, (vii) measuring (141), recording (142) and storing (143) the body metric information (102c) obtained from the at least one measuring device (140) for measuring the body metric information in the database (103), (vii) allowing the medical practitioner (110) specializing in metabolic syndrome and related diseases to access (170) the medical records of the patient for the evaluation of the patient's health status and adjustment or maintenance of a treatment plan (113), and optionally (ix) establishing (114) communication between the patient (100) and the medical practitioner (110) at set time periods or upon request of the patient or the medical practitioner.

8. A system for monitoring at least one body metric information of a patient (100) in need thereof, in order to prevent or reduce the risk of metabolic syndrome and related diseases, using an electronic device, the system comprising: (a) An electronic device and interface (160a) for entering patient identification information and / or body metric information into a database. (b) A device and interface (160b) for collecting and storing said patient identification information and / or said body metric information in said database for incorporation into a medical record. (c) access (170) between said patient and a medical professional specializing in metabolic syndrome and related disorders for the purpose of evaluating said patient's health status. (d) means (170a) for indicating said health condition to said patient and recording it in said medical record; (e) means (170b) for instructing said patient on a course of treatment for treating the metabolic syndrome and / or metabolic syndrome-related disorders from which said patient suffers or for preventing the metabolic syndrome and / or metabolic syndrome-related disorders from which said patient suffers. (f) means for providing (121a) to said patient (100) in need thereof a pharmaceutical composition comprising a pharmaceutical agent useful for the prevention, mitigation, or management of metabolic syndrome and / or related disorders. (g) means for providing (121b) to said patient in need thereof consumables or support devices for the prevention, mitigation, or management of metabolic syndrome and / or related diseases. (h) means for connecting one or more measurement devices for measuring body metric information using an interactive user interface (152); (i) A database (103) for recording and storing the collected body metric information. (j) A means for said medical professional specializing in metabolic syndrome and related diseases to monitor (112) said body metric information data of said patient and evaluate said patient's health condition. (k) access means for said medical practitioner to adjust or maintain said patient's metabolic syndrome and / or related disease treatment or metabolic syndrome and / or disease prevention course (113). (l) Optionally, access means for establishing (114) communication between the patient and the healthcare professional at set intervals or upon request of the patient or the healthcare professional.

9. A method for the measurement, diagnosis, treatment and management of metabolic syndrome using an electronic device, comprising administering a medicinal product to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases, the method comprising: (a) providing a patient and a medical professional with a therapeutic or preventive monitoring system (200) comprising at least an electronic device and interface (160a) for inputting patient identification information and / or body metric information into a database, and a device and interface (160b) for collecting and storing said patient identification information and / or said body metric information in said database for incorporation into a medical record; means for accessing (170) said patient with said medical professional specialized in metabolic syndrome and related diseases to assess said patient's health condition; means for recording (170a) said patient's health condition and in said medical record; means for instructing (170b) said patient on the efficacy or effectiveness of a treatment or prevention of metabolic syndrome and / or metabolic syndrome related diseases; means for providing (121a) said patient in need thereof (100) with a pharmaceutical composition comprising a medicinal product useful for the prevention, alleviation or management of metabolic syndrome and / or related diseases; means for providing (121b) the patient in need thereof with consumables or support devices for the prevention, alleviation or control of metabolic syndrome and / or related diseases; means for connecting (152) one or more measuring devices and an interactive user interface for measuring body metric information; the database (103) for recording and storing the collected body metric information; a method for the medical professional specializing in metabolic syndrome and related diseases to monitor (112) the body metric information data of the patient in order to assess the health status of the patient; access means for the medical professional to adjust or maintain a treatment plan (113) for the treatment of metabolic syndrome and / or related diseases or the prevention of metabolic syndrome and / or related diseases suffered by the patient; and optionally access means for establishing (114) communication between the patient and the medical professional at set time periods or at the request of the patient or the medical professional. (b) providing to the patient (100) a pharmaceutical composition comprising a pharmaceutical agent (130) useful for preventing, alleviating or managing metabolic syndrome and / or related diseases from the patient identification information and volumetric information previously stored in the database or from the patient's medical records. (c) the medical professional (110) specializing in metabolic syndrome and related diseases monitors the patient's body metric information data and assesses the patient's health condition using the interactive user interface connected to one or more measuring devices for measuring the body metric information.

10. 2. A method for measuring, diagnosing, treating and managing metabolic syndrome using the electronic device of claim 1, comprising administering said medicine to said patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases, wherein said body metric information is weight, BMI, body fat percentage, height, muscle, water, visceral fat, bone, metabolism, protein, obesity index, body age, lean body mass, oxygenation, body oxygenation quantified in urine, vitamins and minerals, blood glucose level, blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, urine glucose level, pedometer, heart rate, fasting blood glucose level, post-load blood glucose level, total cholesterol, total bilirubin, alanine transaminase, aspartate aminotransferase and / or body temperature.

11. A method for measuring, diagnosing, treating and managing metabolic syndrome, comprising administering said medicine to said patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device according to claims 1 to 6, characterized in that said measuring device (140) is selected from: weighing scales, ORP, vitamin sticks, blood glucose meters, oximeters, smart watches, smart bracelets, smart clothing, patches, tattoos, implants, hearing aids, helmets, electrodes, chest bands, pedometers, medical equipment for quantification of biochemical parameters.

12. A method for measuring, diagnosing, treating and managing metabolic syndrome, comprising administering said medicinal products to said patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device according to claims 1 to 6, wherein pharmaceutical compositions comprising said medicinal products (130) useful for preventing, reducing or managing metabolic syndrome and / or related diseases include chemical uncouplers of oxidative phosphorylation, tyrphostin AG17, orlistat, L-carnitine, benzphetamine, phendimetrazine, phenoxyethanol ... , diethylpropion, liraglutide, naltrexone, phentermine, topiramate, glibenclamide, metformin, acarbose, canagliflozin, dapagliflozin, saxagliptin, dulaglutide, empagliflozin, exenatide, lixisenatide, semaglutide, CBD, sibutramine, hydroxycitric acid, coenzyme q10, chromium picolinate, gamma-linolenic acid, resveratrol, omega-3 fatty acids, antioxidants, vitamins, vitamin B, vitamin C, adrenal extract, pantothenic acid, turmeric longa), Bayberry bark, Myrica cerifera, Oryza sativa L. indica, Camellia sinensis, Theobroma cacao, Emblica officinalis, Yerba mate, Ilex paraguariensis, Cascara sagrada bark, Rhamnus purshiana, Acacia nilotica, Persimmon, Blueberry leaves leaf), Grape seed, Cordia salicifolia, Hypericum perforatum, Pueruria thomsonn, Capers (Capparis spinosa), Gymnema sylvestre, Elderberry, Sambicus,Citrus aurantium, Coffee tree (Coffea canefora), Sygium cumini, Rosemary (Rosmarinus officinalis), Ginger (Zingiber officinalis), Cassia nomame, Cissus quadrangularis, Phaseolus vulgaris, Licorice root, Fenugreek, Yohimbine, White willow, Cordyceps sinensis, Ashwagandha, Astragalus, Gingseng, Schisandra, Siberian gingseng, Asian gingseng, Guggul, Gagal, Mukul, Commiphora mukul, Momordica charantia, Garcinia cambogia, Althaea officinalis, Bougainvillea spectabilis, Medicago sativa, sativa), Valeriana officinalis, Damiana, Sambucus nigra, Capsicum, Allium, Calcium myristate, Magnesium myristate, Tetradecylthioacetate (TTA), thyroid hormones or precursors thereof, thyroid enhancers, Kreb cycle metabolites, UCP-1, UCP-2, UCP-3, endogenous uncoupling protein of PUMP (plant uncoupling mitochondrial protein) or precursors thereof, agonists or enhancers, leucine, valine, isoleucine, glutamine, proline, tyrosine, conjugated linoleic acid, adrenergic secretagogues, fatty acids or esters, beta agonists, glucagon, albuterol, vasopressin, ubiquinone, coenzyme Q1, coenzyme Q2, melatonin, fatty acid esters of estrogen, glucomannan, menthol,Peppermint oil, thyme oil, elemental sulfur and policosanol, insulin or insulin analogues, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, tolazamide, tolbutamide, (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol or Glyset)(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)-cyclohexane-1,2,3,4-tetraol), (RS)-5-[4-(2-[methyl (pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, (RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione, 5-[(4-[2-([6-(4-methoxyphenoxyl)pyrimidin-4-yl]-methylamino)ethoxy]phenylmethyl]-1,3-thiazolidine-2,4-dione, (RS) -5-(4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)thiazolidine-2,4-dione, (S)-(+)-2-ethoxy-4-[2-(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino)-2-oxoethyl]benzoic acid, 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propan Panic acid, (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol-2-yl]-4-oxobutanoic acid, L-ornithine, L-tyrosine, L-tryptophan, L-phenylalanine, conjugated linoleic acid, γ-linolenic acid, chromium picolinate, glucose tolerance factor, vanadyl sulfate, Gymnema sylvestre, bromelain, pancreatin, Pagymnema sylvestre 10, curcuma Ming, barberry, bearberry, silymarin, fruit fly, choline, inositol, human growth hormone, DHEA, fucoxanthin, caffeine, xanthenes, cola nut, psyllium, mate, guarana, ginseng, medium chain triglycerides, hydroxycitric acid (HCA), kelp, lecithin, dihydroxyacetone, pyruvic acid, creatine, iodine, niacin, bladderwrack,White Kidney Bean Extract, Glucomannan, Chitosan, Resveratrol, Resveratrol Derivatives, Vitamin D, hCG, Capsaicin, Chia, Hoodia, Apple Cider Vinegar, Coconut Oil, Bitter Orange, B Vitamins, Fluoxetine, Chitosan, Chromium Picolinate, Conjugated Linoleic Acid (CLA), Glucomannan, Green Tea Extract, Green Tea Extract, Guar Gum, Hoodia, 7-Keto-DHEA, DHEA, Ephedra, Bitter Orange, Turmetic, Ginger Root Powder, Apple Cider Vinegar, Calcium, Hesperidin, Apanthenol Gynostemma, Flaxseed Oil, Orange Peel Powder, Thiamine, Ashwagandha Extract, Coffee Extract, L-Theanine, Choline Bitartrate, Red Mango Extract, White Kidney Bean Extract, C. A method for the measurement, diagnosis, treatment and management of metabolic syndrome, characterized in that the compound is selected from the group consisting of Cinephora robusta extract, Acetyl-L-carnitine, Garcinia cambogia, Kumbusia extract, coconut oil, Forskolin extract, Black pepper extract, Seroxat, Citalopram, Bupropion, Topiramate, Ecopipam, Naltrexone, Peptide YY3-36, Leptin, Amphetamine, Phentermine, Mazindol, Phendimetrazine, Diethylpropion, Fenfluramine, Dexfenfluramine, Pharmacologically acceptable salts and derivatives thereof, and mixtures thereof.

13. A method for measuring, diagnosing, treating and managing metabolic syndrome comprising administering said pharmaceutical agent to said patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using the electronic device of claim 12, wherein said chemical uncoupler of oxidative phosphorylation is selected from the group consisting of 4,4-bis-(4-hydroxy-3-nitrophenyl)valeric acid, 4-methoxy-2-nitrophenol, 4-hydroxy-3-nitroacetophenone, 7-hydroxy-4-methyl-8-nitrochromen-2-one, 3-tert-butoxy-2-methyl-1,2-dihydro-2,4-triazol-1-yl) ... N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-methylbenzamide, N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3,5-di-(trifluoromethyl)benzamide, N-(4-cyanophenyl)benzamide, 2'-chloro-1-hydroxy-4'-nitro-2-naphthanilide, N-(2-chloro-4-bromophenyl)-5-bromosalicylanilide, N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylanilide, (3,5-di-tert-butyl-4 -hydroxybenzyl)triphenylphosphonium bromide, 3,5-di-tert-butyl-4-hydroxybenzyl)tricyclohexylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tributylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)trioctylphosphonium bromide, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)malonic acid di Ethyl ester, 2-amino-S-[(3,5-di-tert-butyl-4-hydroxybenzylidene)-amino]but-2-enedinitrile, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)-indan-1,3-dione, 2-malononitrile, 2-(4-chlorophenyl)-indole, N-(2,4,5-trichlorophenyl)salicylanilide, 2,3-dimethyl-5-cyano-7-ethylindole, 4-bromo-2-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrrole-3-carbonitrile, N-(5,7-Dimethyl-1H-indol-3-ylmethylene)-3-trifluoromethyl-benzamide, 2,4-dinitrophenol, carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone, 2-(5-bromo-1H-indol-3-ylmethylene)-malononitrile, 2-((5-chloro-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl) methylene)malononitrile, 2-(2-phenyl-3-indolylmethylene)malononitrile, 2-(2-chloro-1H-indol-3-ylmethylene)malononitrile, 2-(5-nitro-1H-indol-3-ylmethylene)malononitrile, 2-(2-methyl-5-nitro-1H-indol-3-ylmethylene)malononitrile, 3-bromo-5-tert-butyl-N-(2-chloro-4-nitrophenyl)-6-hydroxy-2-methylbenzamide, N-(2-chloro-4-nitrophenyl)- N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-6-methylbenzamide, 3,5-di-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide, 3-bromo-N-(2-chloro-4-nitrophenyl)-6-hydroxy-5-isopropyl-2-methylbenzamide, 3-tert-butyl-5-chloro-N-(4-chloro-3-trifluoromethylphenyl)-2-hydroxy hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-N-(4-cyano-3-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 2-hydroxybiphenyl-3-carboxylic acid (2-chloro-4-nitrophenyl)-amide, 3-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxy-5-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-isopropyl-3-methylbenzamide, N-(3,5-bistrifluoromethylphenyl)-3-tert-butyl-5-chloro-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-N-(2-fluoro-5-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-3-trifluoromethylphenyl)benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3 -bromo-5-tert-butyl-N-(2-chloro-4-cyanophenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(2-chloro-5-trifluoromethylphenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methyl benzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-{5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl}-6-hydroxy-2-methylbenzamide, 3-bromo-6-hydroxy-5-isopropyl-2-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N- (4-nitro-2-trifluoromethylphenyl)benzamide, 3-tert-butyl-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-N-(3,5-di-tert-butyl-4-hydroxyphenyl)-5-tert-butyl-6-hydroxy-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-bromo-5-tert-butyl-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-[(3,5-di-tert-butyl-4-hydroxybenzylidene)amino]-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-6-hydroxy-N-(4-isopropyl-2-trifluoromethylphenyl)-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-fluoro-5-trifluoromethylbenzamide, 3-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-5-trifluoromethylbenzamide, N-(2,4,5 4-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-3-trifluoromethylbenzamide, 3-(3,5-di-tert-butyl-4-hydroxyphenyl-2-(5,7-dimethyl-1H-indol-3-ylmethylene)acrylonitrile, 2-acetyl-3-(3,5-bis-trifluoromethylphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononyl tolyl, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononitrile, 2,6-di-tert-butyl-4-nitrophenol, 2-tert-butyl-4,6-dinitrophenol, 3-(3,5-di-tert-butyl-4-hydroxybenzyl)-2-pyridin-2-yl-acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)malononitrile, 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-(diethylphosphonate)propenenitrile , 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-nitrophenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-pyridin-4-yl-acrylonitrile, 2-(3,5-bis-trifluoromethylphenyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethoxyphenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethylphenyl)acrylonitrile, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)but-2-enoic acid ethyl ester, N-(4-chlorophenyl)-2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylamide, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methanesulfonylacrylonitrile, (E)-2-(4-chlorobenzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-fluorobenzenesulfonyl)acrylonitrile, (E)-2-benzenesulfonyl-3- (3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-bis-trifluoromethylphenyl)-2-(propane-2-sulfonyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(hexane-1-sulfonyl)acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 2-(4-bromo-benzenesulfonyl)-3-acrylonitrile, 2-(3,A method for measuring, diagnosing, treating, and managing metabolic syndrome, characterized in that the compound is selected from the group consisting of 5-di-tert-butyl-4-hydroxybenzylidene)acrylonitrile, 5-bromo-3-tert-butyl-N-(2-chloro-4-cyanophenyl)-2-hydroxybenzamide, 5-bromo-3-tert-butyl-N-(4-cyanophenyl)-2-hydroxybenzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(2-trifluoromethylphenyl)benzamide, 2-(2-bromo-1H-indol-3-ylmethylene)malononitrile, 2-(7-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, 2-(5-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, pharma- ceutically acceptable salts thereof, derivatives thereof, and mixtures thereof.

14. A method for measuring, diagnosing, treating and managing metabolic syndrome using the electronic device of claim 1, comprising administering said pharmaceutical to said patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases, said pharmaceutical composition comprising said pharmaceutical comprises a pharmaceutical for the prevention, reduction or management of hypertension, said pharmaceutical being selected from the group consisting of alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, benazepril, captopril, A method for measuring, diagnosing, treating and managing metabolic syndrome, characterized in that the therapeutic agent is selected from ACE (angiotensin converting enzyme) inhibitors including enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers including nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and [alpha]-blockers including doxazosin, urapidil, prazosin and terazosin, and pharma- ceutically acceptable salts and derivatives thereof, and mixtures thereof.

15. A method for measuring, diagnosing, treating and managing metabolic syndrome using the electronic device of claim 1, comprising administering said pharmaceutical to said patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases, said pharmaceutical composition comprising said pharmaceutical (130) being selected from the group consisting of tyrphostin AG, tyrphostin A9, insulin and insulin analogues, tolbutamide, chlorpropamide, tolazamide, glibenclamide, glipizide, glimepiride, glicazide / glyburide, metformin, repaglipidine, ribavirin ... Nido, senaglinide, nateglinide, troglitazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, GI262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H, voglibose, emiglitate, miglitol / acarbose, tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582o repaglinide, nateglinide, cholestyramine, colestipol, clofibrate, gemuf ivrozil, lovastatin, pravastatin, simvastatin, chemical uncouplers of oxidative phosphorylation or derivatives thereof, drugs acting on the ATP-dependent potassium channel of pancreatic [β] cells, biguanides, imidazolines, [α]-glucosidase inhibitors, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, sulfonylureas, potassium channel blockers such as nateglinide or BTS-67582, glucagon antagonists, DPP-IV (dipeptidyl peptidase-IV) inhibitors and a method for measuring, diagnosing, treating and managing metabolic syndrome, characterized in that the active ingredient is selected from the group consisting of lipid metabolism modifying agents, PTPase (protein tyrosine phosphatase) inhibitors, glucokinase activators, inhibitors of liver enzymes involved in stimulating gluconeogenesis and / or glycogenolysis, glucose uptake regulators, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds that modify lipid metabolism such as antihyperlipidemic and antilipidemic agents, compounds that reduce food intake and PPAR agonists, and pharma- ceutically acceptable salts and derivatives thereof, and mixtures thereof.

16. A method for the measurement, diagnosis, treatment and management of overweight and obesity, comprising administering a medicinal product to a patient (100) in need thereof to prevent or reduce the risk of overweight and obesity using an electronic device, the method comprising the steps of: (a) Collecting (101) patient identification information (102a) and / or body metric information (102c) and storing it in a database (103) for incorporation into a medical record (102b). (b) connecting said patient (100) with a medical professional (110) who specializes in overweight and obesity to assess their health status. (c) indicating said health condition (111b) to said patient and recording it in said medical record (102b); (d) instructing (111c) said patient on a course of treatment for treating or preventing the overweight and obesity suffered by said patient. (e) providing (121a) through a pharmacy (120) to said patient (100) in need thereof a pharmaceutical product (130), pharmaceutical composition useful for the prevention, reduction, or management of overweight and obesity. (f) providing (121b) through said pharmacy (120) to a patient (100) in need thereof a consumable (140a) or support device (140b) for the prevention, reduction or management of overweight and obesity. (g) connecting (151) one or more measuring devices (140) for measuring said body metric information using an interactive user interface (150). (h) measuring (141), recording (142) and storing (143) the collected body metric information (102c) in the database (103). (i) The medical professional (110) specializing in overweight and obesity monitors (112) the patient's (100) body metric information (102c) data and assesses the patient's health condition. (j) adjusting or maintaining said patient's treatment of overweight and obesity or prevention of overweight and obesity (113). (k) optionally, said medical personnel (110) providing assistance (114) to said patient (100) at defined time periods and upon request of said patient or said medical personnel.

17. A method for the measurement, diagnosis, treatment and management of overweight and obesity, comprising administering a medicinal product to a patient in need thereof to prevent or reduce the risk of overweight and obesity using an electronic device, the method comprising the following features: (a) Providing (121a) to a patient (100) a pharmaceutical composition comprising a medicinal product (130) useful for the prevention, reduction or management of overweight and obesity from patient identification information (102a) and body metric information (102c) and / or medical records (102b) previously stored in a database (103). (b) A medical professional (110) specializing in overweight and obesity monitors (112) the body metric information data of a patient to assess a health condition using an interactive user interface (150) connected to one or more measuring devices for measuring the body metric information, and the interactive user interface (150) records (142) and stores (143) the body metric information.

18. A method for the measurement, diagnosis, treatment and management of overweight and obesity, comprising administering a pharmaceutical agent to a patient undergoing treatment for the prevention, reduction or management of overweight and obesity using an electronic device, the method comprising the following features: (a) Patient identification information (102a) and / or body metric information (102c) are collected (101) and stored in a database (103) for incorporation into the medical record (102b). (b) providing (121a) to said patient (100) in need thereof, through a pharmacy (120), a pharmaceutical composition comprising a pharmaceutical product (130) useful for preventing, reducing or managing overweight and obesity, based on said patient identification information (102a) and said patient's body metric information (102c) and / or said patient's medical records (102b) previously stored in said database. (c) measuring (141), recording (142) and storing (143) the patient's body metric information (102c) collected during treatment in the database (103); (d) A medical professional (110) specializing in overweight and obesity monitors (112) the body metric information (102c) data of the patient (100) and assesses the health status of the patient. (e) adjusting or maintaining a treatment regimen (113) for the treatment of overweight and obesity or for the prevention of overweight and obesity from which said patient suffers.

19. A method for the measurement, diagnosis, treatment and management of overweight and obesity, comprising administering a medicinal product to a patient in need thereof to prevent or reduce the risk of overweight and obesity using an electronic device, the method comprising the following features: (a) A patient (100) is introduced (111) to a health care professional (110) who specializes in overweight and obesity, who assesses the health status of the patient. (b) displaying (111b) said health condition to said patient and recording it in their medical record (102b); (c) instructing said patient (111c) on a course of treatment for treating or preventing the overweight and obesity suffered by said patient. (d) providing (121a) through a pharmacy (120) a pharmaceutical composition comprising a pharmaceutical agent (130) useful for the prevention, reduction or management of overweight and obesity to said patient (100) in need thereof. (e) Recording (142) and storing (143) in a database (103) body metric information (102c) collected from the patient during treatment. (f) The medical professional (110) specializing in overweight and obesity monitors (112) the body metric information (102c) data of the patient (100) and assesses the health condition. (g) adjusting or maintaining said patient's treatment of overweight and obesity or prevention of overweight and obesity (113).

20. A method for the measurement, diagnosis, treatment and management of overweight and obesity, comprising administering a medicinal product to a patient in need thereof to prevent or reduce the risk of overweight and obesity using an electronic device, the method comprising the following features: (a) Providing (121a) through a pharmacy (120) a pharmaceutical composition comprising a pharmaceutical agent (130) useful for the prevention, reduction or management of overweight and obesity to a patient (100) in need thereof. (b) providing (121b) through said pharmacy (120) to said patient (100) in need thereof consumables (140a) or support devices (140b) for the prevention, reduction or management of overweight and obesity. (c) connecting (151) one or more measurement devices (140) for measuring body metric information using an interactive user interface (150); (d) measuring (141), recording (142) and storing (143) the collected body metric information (102c) in a database (103); (e) A medical professional (110) specializing in overweight and obesity monitors (112) the body metric information (102c) data of the patient (100) and assesses the health condition of the patient. (f) adjusting or maintaining said patient's treatment of overweight and obesity or prevention of overweight and obesity (113).

21. 1. A method for the measurement, diagnosis, treatment and management of overweight and obesity, comprising: A method for the measurement, diagnosis, treatment and management of overweight and obesity using an electronic device to administer a medicinal drug to a patient in need thereof to prevent or reduce the risk of overweight and obesity, the method comprising the following features: (a) Providing (121a) through a pharmacy (120) a pharmaceutical composition comprising a pharmaceutical agent (130) useful for preventing, reducing or managing overweight and obesity disorders to a patient (100) in need thereof. (b) connecting (151) one or more measurement devices (140) for measuring body metric information using an interactive user interface (150); (c) The collected body metric information (102c) is measured (141), recorded (142), and stored (143) in a database (103). (d) A medical professional (110) specializing in overweight and obesity monitors (112) the body metric information (102c) data of the patient (100) and assesses the health condition of the patient. (e) adjusting or maintaining said patient's treatment of overweight and obesity or prevention of overweight and obesity (113).

22. A system for monitoring at least one body metric information of a patient (100) in need thereof, in order to prevent or reduce the risk of overweight and obesity, using an electronic device associated with a device for measuring said body metric information, the system comprising: (a) A patient monitoring module installed in a patient electronic device and interface (160a). (b) at least one measuring device (140) for measuring body metric information connectable to said electronic device and interface (160a) of said patient; (c) having means of communication (180) between said electronic device and interface (160a) of said patient and a measuring device (140) for measuring said body metric information; The patient monitoring module is configured to (i) collect (101) patient identification information (102a) and / or the body metric information (102c), (ii) measure (141), record (142) and store (143) the collected body metric information (102c) of the patient in a database (103), (iii) store the information in the database (103) for incorporation into a medical record (102b), and (iv) refer (111) the patient (100) to a medical professional (110) specializing in overweight and obesity, evaluate the patient's health status, inform the patient of the health status (111b), record in the medical record (102b), and advise (111c) a course of treatment for the overweight and obesity suffered by the patient or for the prevention of overweight and obesity. (v) providing (121a) through a pharmacy (120) to said patient (100) in need thereof a pharmaceutical composition comprising a pharmaceutical agent (130) useful for the prevention, reduction or management of overweight and obesity, as well as consumables (140a) or support devices (140b). (vi) establishing a connection (151) with at least one said measuring device (140) for measuring said body metric information; (vii) measuring (141), recording (142) and storing (143) in said database (103) said body metric information (102c) obtained from at least one said measuring device (140) for measuring said body metric information; (vii) allowing said medical practitioner (110) specializing in overweight and obesity to access (170) said medical records of said patient for the assessment of said health condition and adjustment or maintenance of said treatment plan (113); and optionally (ix) establishing (114) communication between said patient (100) and said medical practitioner (110) at established time periods or upon request of said patient or said medical practitioner.

23. A system for monitoring at least one body metric information of a patient (100) in need thereof, in order to prevent or reduce the risk of overweight and obesity, using an electronic device, the system comprising: (a) An electronic device and interface (160a) for entering patient identification information and / or body metric information into a database. (b) A device and interface (160b) for collecting and storing said patient identification information and / or said body metric information in a database for incorporation into a medical record. (c) access (170) between said patient and a medical professional specializing in overweight and obesity to assess said patient's health status. (d) means (170a) for indicating said health condition to said patient and recording it in said medical record; (e) means for instructing said patient on a course of treatment for treating or preventing overweight and obesity from which said patient suffers (170b). (f) means for providing (121a) to said patient (100) in need thereof a pharmaceutical composition comprising a pharmaceutical agent useful for the prevention, reduction or management of overweight and obesity. (g) providing (121b) to said patient in need thereof a consumable or support device for the prevention, reduction or control of overweight and obesity. (h) means for connecting (152) one or more measuring devices for measuring said body metric information using an interactive user interface; (i) The database (103) for recording and storing the collected body metric information. (j) A means for said medical professional specializing in overweight and obesity to monitor (112) said body metric information data of said patient and assess said patient's health condition. (k) access means for said health care professional to adjust or maintain the patient's overweight and obesity treatment or overweight and obesity prevention treatment course (113). (l) Optionally, access means for establishing (114) communication between the patient and the healthcare professional at set intervals or upon request of the patient or the healthcare professional.

24. A method for the measurement, diagnosis, treatment and management of overweight and obesity, comprising administering a medicinal product to a patient in need thereof to prevent or reduce the risk of overweight and obesity using an electronic device, the method comprising the following features: (a) comprising at least an electronic device and interface (160a) for inputting patient identification information and / or body metric information into a database, and an electronic device and interface (160b) for collecting and storing said patient identification information and / or body metric information in said database in order to provide a therapeutic or preventive monitoring system (200) to a patient and a medical professional and to incorporate said monitoring system into a medical record; means for accessing (170) between said patient and said medical professional specializing in metabolic syndrome and related diseases in order to evaluate said patient's health condition; means for recording (170a) said patient's health condition and said medical record; means for instructing (170b) said patient on a course of treatment for the treatment or prevention of overweight and obesity; means for providing (121a) said patient (100) in need thereof with a pharmaceutical composition comprising a medicinal product useful for the prevention, reduction or management of overweight and obesity. means for providing (121b) to the patient in need consumables or support devices for the prevention, reduction or management of overweight and obesity; means for connecting (152) with an interactive user interface for one or more measuring devices for measuring the body metric information; the database (103) for recording and storing the collected body metric information; a method for a medical professional specializing in overweight and obesity to monitor (112) the body metric information data of the patient in order to assess the health condition of the patient; access means for the medical professional to adjust or maintain a treatment plan (113) for the treatment of the patient's overweight and obesity or the prevention of overweight and obesity; optionally, access means for establishing (114) communication between the patient and the medical professional at set time periods or at the request of the patient or the medical professional. (b) providing said patient (100) with a pharmaceutical composition comprising a pharmaceutical agent (130) useful for preventing, reducing, or managing overweight and obesity based on said patient identification information and said body metric information, or said medical records of said patient previously stored in said database. (c) the medical professional (110) specializing in metabolic syndrome and related diseases monitors the body metric information data of the patient using an interactive user interface connected to one or more measuring devices for measuring the body metric information and evaluates the health condition of the patient.

25. 22. A method for measuring, diagnosing, treating and managing overweight and obesity comprising administering said medicinal product to said patient (100) in need thereof to prevent or reduce the risk of overweight and obesity using an electronic device according to claims 16 to 21, characterized in that said body metric information is selected from weight, body mass index, percentage of body fat, height, muscle, water, visceral fat, bone, metabolism, protein, obesity index, body age, lean body mass, oxygenation, body oxygenation quantified in urine, vitamins and minerals, blood glucose, blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, urine glucose, pedometer, heart rate, fasting blood glucose, post-load blood glucose, total cholesterol, total bilirubin, alanine transaminase, aspartate aminotransferase and / or body temperature.

26. 22. A method for measuring, diagnosing, treating and managing overweight and obesity comprising administering said medicine to said patient (100) in need thereof to prevent or reduce the risk of overweight and obesity using an electronic device according to claims 16 to 21, characterized in that said measuring device (140) is selected from: weighing scales, ORP, vitamin sticks, blood glucose meters, oximeters, smart watches, smart bracelets, smart clothing, patches, tattoos, implants, hearing aids, helmets, electrodes, chest bands, pedometers, medical equipment for quantification of biochemical parameters.

27. A method for the measurement, diagnosis, treatment and management of overweight and obesity, comprising administering said medicinal product to said patient (100) in need thereof, for preventing or reducing the risk of overweight and obesity, using an electronic device according to claims 16 to 21, wherein the pharmaceutical composition comprising said medicinal product (130) useful for preventing, reducing or managing overweight and obesity is selected from the group consisting of chemical uncouplers of oxidative phosphorylation, tyrphostin AG17, orlistat, L-carnitine, benzphetamine, phendimetrazine, diethylpropion, rilag. Lutide, naltrexone, phentermine, topiramate, glibenclamide, metformin, acarbose, canagliflozin, dapagliflozin, saxagliptin, dulaglutide, empagliflozin, exenatide, lixisenatide, semaglutide, CBD, sibutramine, hydroxycitric acid, coenzyme q10, chromium picolinate, gamma-linolenic acid, resveratrol, omega-3 fatty acids, antioxidants, vitamins, vitamin B, vitamin C, adrenal extract, pantothenic acid, turmeric longa), Bayberry bark, Myrica cerifera, Oryza sativa L. indica, Camellia sinensis, Theobroma cacao, Emblica officinalis, Yerba mate, Ilex paraguariensis, Cascara sagrada bark, Rhamnus purshiana, Acacia nilotica, Persimmon, Blueberry leaves leaf), grape seed, Cordia salicifolia, Hypericum perforatum, Pueruria thomsonn, Capers (Capparis spinosa), Gymnema sylvestre, Elderberry, Sambicus, Citrus aurantium,Robusta coffee tree (Coffea canefora), purple myrtle (Sygium cumini), rosemary (Rosmarinus officinalis), ginger (Zingiber officinalis), Cassia nomame, Cissus quadrangularis, kidney bean (Phaseolus vulgaris), licorice root, fenugreek, yohimbine, white willow, cordyceps sinensis, Ashwagandha, Astragalus, Gingseng, Schisandra, Siberian gingseng, Asian gingseng, Guggul, Gagal, Mukul, Commiphora mukul, Momordica charantia, Garcinia cambogia, Althaea officinalis, Bougainvillea spectabilis, Medicago sativa, sativa), Valeriana officinalis, Damiana, Sambucus nigra), Capsicum, Allium, calcium myristate, magnesium myristate, tetradecylthioacetic acid (TTA), thyroid hormones or precursors thereof, thyroid enhancers, Kreb cycle metabolites, UCP-1, UCP-2, UCP-3, endogenous uncoupling proteins or precursors of PUMP (plant uncoupling mitochondrial protein), agonists or enhancers, leucine, valine, isoleucine, glutamine, proline, tyrosine, conjugated linoleic acid, adrenergic secretagogues, fatty acids or esters, beta agonists, glucagon, arbutamine, vasopressin, ubiquinone, coenzyme Q1, coenzyme Q2, melatonin, fatty acid esters of estrogen, glucomannan, menthol, peppermint essential oil, thyme essential oil,Elemental sulfur and policosanol, insulin or insulin analogues, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, tolazamide, tolbutamide, (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol or Glyset)(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)-cyclohexane-1,2,3,4-tetraol), (RS)-5-[4-(2-[methyl (pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, (RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione, 5-[(4-[2-([6-(4-methoxyphenoxyl)pyrimidin-4-yl]-methylamino)ethoxy]phenylmethyl]-1,3-thiazolidine-2,4-dione, (RS)-5-( 4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)thiazolidine-2,4-dione, (S)-(+)-2-ethoxy-4-[2-(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino)-2-oxoethyl]benzoic acid, 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid, (2S)- 2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol-2-yl]-4-oxobutanoic acid, L-ornithine, L-tyrosine, L-tryptophan, L-phenylalanine, conjugated linoleic acid, γ-linolenic acid, chromium picolinate, glucose tolerance factor, vanadyl sulfate, Gymnema sylvestre, bromelain, pancreatin, Pagymnema sylvestre 10, curcumin, barberry, bearberry , silymarin, fruit fly, choline, inositol, human growth hormone, DHEA, fucoxanthin, caffeine, xanthenes, cola nut, psyllium, yerba mate, guarana, ginseng, medium chain triglycerides, hydroxycitric acid (HCA), kelp, lecithin, dihydroxyacetone, pyruvic acid, creatine, iodine, niacin, bladderwrack, white kidney bean extract, glucomannan,Chitosan, Resveratrol, Resveratrol Derivatives, Vitamin D, hCG, Capsaicin, Chia, Hoodia, Apple Cider Vinegar, Coconut Oil, Bitter Orange, B Vitamins, Fluoxetine, Chitosan, Chromium Picolinate, Conjugated Linoleic Acid (CLA), Glucomannan, Green Tea Extract, Green Tea Extract, Guar Gum, Hoodia, 7-Keto-DHEA, DHEA, Ephedra, Bitter Orange, Turmetic, Ginger, Root Powder, Apple Cider Vinegar, Calcium, Hesperidin, Apanthenol Gynostemma, Flaxseed Oil, Orange Peel Powder, Thiamine, Ashwagandha Extract, Coffee Extract, L-Theanine, Choline Bitartrate, Red Mango Extract, White Kidney Bean Extract, C. A method for the measurement, diagnosis, treatment and management of overweight and obesity, characterized in that the active ingredient is selected from Cinephora robusta extract, Acetyl-L-Carnitine, Garcinia cambogia, Kumbusia extract, Coconut oil, Forskolin extract, Black pepper extract, Seroxat, Citalopram, Bupropion, Topiramate, Ecopipam, Naltrexone, Peptide YY3-36, Leptin, Examephetamine, Amphetamine, Phentermine, Mazindol, Phendimetrazine, Diethylpropion, Fenfluramine, Dexfenfluramine, Pharmacologically acceptable salts and derivatives thereof and mixtures thereof.

28. A method for measuring, diagnosing, treating and managing overweight and obesity comprising administering said pharmaceutical to said patient (100) in need thereof to prevent or reduce the risk of overweight and obesity using the electronic device of claim 27, wherein said chemical uncoupler of oxidative phosphorylation is selected from the group consisting of 4,4-bis-(4-hydroxy-3-nitrophenyl)valeric acid, 4-methoxy-2-nitrophenol, 4-hydroxy-3-nitroacetophenone, 7-hydroxy-4-methyl-8-nitrochromen-2-one, 3-tert-butyl-5-chloro-N- (2-chloro-4-nitrophenyl)-2-hydroxy-6-methylbenzamide, N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3,5-di-(trifluoromethyl)benzamide, N-(4-cyanophenyl)benzamide, 2'-chloro-1-hydroxy-4'-nitro-2-naphthanilide, N-(2-chloro-4-bromophenyl)-5-bromosalicylanilide, N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylanilide, (3,5-di-tert-butyl-4-hydroxybenzamide (3,5-di-tert-butyl-4-hydroxybenzyl)tricyclohexylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tributylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)trioctylphosphonium bromide, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)diethyl malonate ester, 2-amino-S-[(3,5-di-tert-butyl-4-hydroxybenzylidene)-amino]but-2-enedinitrile, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)indan-1,3-dione, 2-malononitrile, 2-(4-chlorophenyl)indole, N-(2,4,5-trichlorophenyl)salicylanilide, 2,3-dimethyl-5-cyano-7-ethylindole, 4-bromo-2-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrrole-3-carbonitrile, N-(5,7-Dimethyl-1H-indol-3-ylmethylene)-3-trifluoromethyl-benzamide, 2,4-dinitrophenol, carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone, 2-(5-bromo-1H-indol-3-ylmethylene)malononitrile, 2-((5-chloro-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-(2-phenyl-3-indolylmethylene)malononitrile, 2-(2-chloro-1H-indol-3-ylmethylene)malononitrile, 2-(5-nitro-1H-indol-3-ylmethylene)malononitrile, 2-(2-methyl-5-nitro-1H-indol-3-ylmethylene)malononitrile, 3-bromo-5-tert-butyl-N-(2-chloro-4-nitrophenyl)-6-hydroxy-2-methylbenzamide, N-(2-chloro-4-nitrophenyl)malononitrile N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-6-methylbenzamide, 3,5-di-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide, 3-bromo-N-(2-chloro-4-nitrophenyl)-6-hydroxy-5-isopropyl-2-methylbenzamide, 3-tert-butyl-5-chloro-N-(4-chloro-3-trifluoromethylphenyl)-2-hydro 2-Hydroxybiphenyl-3-carboxylic acid (2-chloro-4-nitrophenyl)-amide, 3-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxy-5-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-isopropyl-3-methylbenzamide, N-(3,5-bistrifluoromethylphenyl)-3-tert-butyl-5-chloro-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-N-(2-fluoro-5-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-3-trifluoromethylphenyl)benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3- Bromo-5-tert-butyl-N-(2-chloro-4-cyanophenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(2-chloro-5-trifluoromethylphenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide amide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-{5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl}-6-hydroxy-2-methylbenzamide, 3-bromo-6-hydroxy-5-isopropyl-2-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-( 4-nitro-2-trifluoromethyl-phenyl)benzamide, 3-tert-butyl-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-N-(3,5-di-tert-butyl-4-hydroxyphenyl)-5-tert-butyl-6-hydroxy-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-bromo-5-tert-butyl-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-[(3,5-di-tert-butyl-4-hydroxybenzylidene)amino]-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-6-hydroxy-N-(4-isopropyl-2-trifluoromethylphenyl)-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-fluoro-5-trifluoromethylbenzamide, 3-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-5-trifluoromethylbenzamide, N-(2,4,5 4-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-3-trifluoromethylbenzamide, 3-(3,5-di-tert-butyl-4-hydroxyphenyl-2-(5,7-dimethyl-1H-indol-3-ylmethylene)acrylonitrile, 2-acetyl-3-(3,5-bis-trifluoromethylphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononyl tolyl, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononitrile, 2,6-di-tert-butyl-4-nitrophenol, 2-tert-butyl-4,6-dinitrophenol, 3-(3,5-di-tert-butyl-4-hydroxybenzyl)-2-pyridin-2-yl-acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)malononitrile, 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-(diethylphosphonate)propenenitrile , 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-nitrophenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-pyridin-4-yl-acrylonitrile, 2-(3,5-bis-trifluoromethylphenyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethoxyphenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethyl-phenyl)acrylonitrile, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)but-2-enoic acid ethyl ester, N-(4-chlorophenyl)-2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylamide, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methanesulfonylacrylonitrile, (E)-2-(4-chlorobenzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-fluorobenzenesulfonyl)acrylonitrile, (E)-2-benzenesulfonyl-3- (3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-bis-trifluoromethylphenyl)-2-(propane-2-sulfonyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(hexane-1-sulfonyl)acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 2-(4-bromo-benzenesulfonyl)-3-acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)acrylonitrile, 5-bromo-3-tert-butyl-N-(2-chloro-4-cyanophenyl)-2-hydroxybenzamide, 5-bromo-3-tert-butyl-N-(4-cyanophenyl)-2-hydroxybenzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(2-trifluoromethylphenyl)benzamide, 2-(2-bromo-1H-indol-3-ylmethylene)malononitrile, 2-(7-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, 2-(5-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, pharma- ceutically acceptable salts and derivatives thereof, and mixtures thereof,

29. A method for the measurement, diagnosis, treatment and management of overweight and obesity comprising administering a medicinal product to a patient (100) in need thereof to prevent or reduce the risk of overweight and obesity using an electronic device according to claims 16 to 21, wherein the pharmaceutical composition comprising said medicinal product (130) comprises a medicinal product for the prevention, reduction or management of hypertension, said medicinal products being selected from the group consisting of alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, benazepril, captopril, enalapril, 2. A method for the measurement, diagnosis, treatment and management of overweight and obesity, characterized in that the drug is selected from ACE (angiotensin converting enzyme) inhibitors, including fosinopril, lisinopril, quinapril and ramipril; calcium channel blockers, including nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil; and [alpha]-blockers, such as doxazosin, urapidil, prazosin and terazosin, pharma- ceutically acceptable salts and derivatives thereof, and mixtures thereof.

30. A method for measuring, diagnosing, treating and managing overweight and obesity, comprising administering a medicinal product to a patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device according to claims 16 to 21, said pharmaceutical composition comprising said medicinal product (130) being selected from the group consisting of tyrphostin AG, tyrphostin A9, insulin and insulin analogues, tolbutamide, chlorpropamide, tolazamide, glibenclamide, glipizide, glimepiride, glicazide / glyburide, metformin, repaglinide or Senaglinide / nateglinide, troglitazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, GI262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H, voglibose, emiglitate, miglitol / acarbose, tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582o repaglinide, nateglinide, cholestyramine, colestipol, clofibrate, gemcitabine, Fibrogil, lovastatin, pravastatin, simvastatin, chemical uncouplers of oxidative phosphorylation or derivatives thereof, drugs acting on the ATP-dependent potassium channel of pancreatic [β] cells, biguanides, imidazolines, [α]-glucosidase inhibitors, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, sulfonylureas, potassium channel blockers such as nateglinide or BTS-67582, glucagon antagonists, DPP-IV (dipeptidyl peptidase-IV) and methods for the measurement, diagnosis, treatment and management of overweight and obesity, characterized in that the active ingredient is selected from the group consisting of lipid metabolism modifying agents, such as ...

Images